Theravance Biopharma (TBPH) Income from Discontinued Operations (2022 - 2023)
Theravance Biopharma's (TBPH) quarterly Income from Discontinued Operations came in at 400000.0 in Q1 2023, up 110.27% on a QoQ basis from 3894000.0 in Q4 2022.
Theravance Biopharma (TBPH) Income from Discontinued Operations (2022 - 2023) Analysis & Trends
Theravance Biopharma (TBPH) has 2 years of Income from Discontinued Operations data on file, last reported at 400000.0 in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Discontinued) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Theravance Biopharma | 864.56 Mn | 469.90 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 400,000.00 |
| Dec 31, 2022 | -3.89 Mn |
| Sep 30, 2022 | 182.36 Mn |